Fig. 3: ctDNA status in the post-definitive treatment surveillance window is predictive of DFS in post-surgical patients with CRC. | npj Precision Oncology

Fig. 3: ctDNA status in the post-definitive treatment surveillance window is predictive of DFS in post-surgical patients with CRC.

From: Validation of a methylation-based, tissue-free MRD assay in colorectal cancer patients from the GALAXY study

Fig. 3: ctDNA status in the post-definitive treatment surveillance window is predictive of DFS in post-surgical patients with CRC.

a Kaplan–Meier analysis of DFS and plasma ctDNA status during the post-definitive treatment surveillance window. The bar plot shows the association between ctDNA status during the post-definitive treatment surveillance window and relapse during the study period. b Forest plot depicting the multivariate analysis (including ctDNA status during the post-definitive treatment surveillance window and clinicopathological features) for DFS. Various prognostic factors and their association with DFS, as indicated by HR, were analyzed across the cohort using the two-sided Wald chi-square test. The unadjusted HRs (black squares) and 95% CIs (horizontal lines) are shown for each prognostic factor. The vertical line is the null hypothesis.

Back to article page